参考文献/References:
[1]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132. [2]Kimura T,Egawa S.Epidemiology of prostate cancer in Asian countries[J].International Journal of Urology,2018,25(6):524-531. [3]Kuriyama M,Wang MC,Lee CI,et al.Use of human prostate-specific antigen in monitoring prostate cancer[J].Cancer Res,1981,41(10):3874-3876. [4]Toussi A,Stewart-Merrill SB,Boorjian SA,et al.Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression[J].Journal of Urology,2016,195(6):1754-1759. [5]van den Broeck T,van den Bergh RCN,Briers E,et al.Biochemical Recurrence in Prostate Cancer:The European Association of Urology Prostate Cancer Guidelines Panel Recommendations[J].European Urology Focus,2020,6(2):231-234. [6]Kang HW,Jung HD,Lee JY,et al.Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer[J].Asian J Androl,2016,18(3):480-484. [7]Peng C,Zhang J,Hou J.Performance characteristics of prostate-specific antigen density and biopsy primary Gleason score to predict biochemical failure in patients with intermediate prostate cancer who underwent radical prostatectomy[J].Cancer Manag Res,2019(11):1133-1139. [8]Hashimoto T,Ohori M,Shimodaira K,et al.Prostate‐specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer[J].International Journal of Urology,2018,25(6):561-567. [9]Sugano D,Sidana A,Jain AL,et al.Index tumor volume on MRI as a predictor of clinical and pathologic outcomes following radical prostatectomy[J].International Urology and Nephrology,2019,51(8):1349-1355. [10]Meyer CP,Hansen J,Boehm K,et al.Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins[J].World Journal of Urology,2017,35(2):199-206. [11]Kir G,Arikan EA,Seneldir H,et al.Determining the cut-off values of tumor diameter,degree of extraprostatic extension,and extent of surgical margin positivity with regard to biochemical recurrence of prostate cancer after radical prostatectomy[J].Ann Diagn Pathol,2020(44):151431. [12]Song W,Lee DH,Jeon HG,et al.Impact of Gleason score on biochemical recurrence in patients with pT3aN0/Nx prostate cancer with positive surgical margins:a multicenter study from the Prostate Cancer Research Committee[J].Journal of Cancer Research and Clinical Oncology,2017,143(11):2393-2400. [13]Park J,Yoo S,Cho MC,et al.The Impact of Pathologic Upgrading of Gleason Score 7 Prostate Cancer on the Risk of the Biochemical Recurrence after Radical Prostatectomy[J].BioMed Research International,2018(2018):1-6. [14]Ettel M,Kong M,Lee P,et al.Modification of the pT2 substage classification in prostate adenocarcinoma[J].Hum Pathol,2016(56):57-63. [15]Billis A,Freitas L,Costa L,et al.The TNM 8th edition:Validation of the proposal for organ -confined(pT2) prostate cancer[J].Int Braz J Urol,2019,45(2):229-236. [16]Roux V,Eyraud R,Brureau L,et al.Impact du score de Gleason sur la survie sans récidive biologique après prostatectomie totale pour cancer avec marges chirurgicales positives[J].Progrès en Urologie,2017,27(8-9):467-473. [17]Bakavicius A,Drevinskaite M,Daniūnaite K,et al.The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival[J].Medicina,2020,56(2):61. [18]Preisser F,Coxilha G,Heinze A,et al.Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer[J].The Prostate,2019,79(16):1832-1836. [19]方志伟,胡浩,梁晨,等.前列腺癌根治术切缘阳性对患者术后生化复发的影响[J].临床泌尿外科杂志,2017,32(9):678-681. [20]Oikawa M,Tanaka T,Narita T,et al.Impact of the Proportion of Biopsy Positive Core in Predicting Biochemical Recurrence in Patients with Pathological Pt2 and Negative Resection Margin Status after Radical Prostatectomy[J].Pathology&Oncology Research,2020,26(4):2115-2121. [21]Kang M,Oh JJ,Lee S,et al.Perineural Invasion and Lymphovascular Invasion are Associated with Increased Risk of Biochemical Recurrence in Patients Undergoing Radical Prostatectomy[J].Annals of Surgical Oncology,2016,23(8):2699-2706. [22]杨超.腹腔镜前列腺癌根治术后生化复发的危险因素分析[D].吉林大学,2019. [23]Reeves FA,Battye S,Roth H,et al.Prostatic nerve subtypes independently predict biochemical recurrence in prostate cancer[J].Journal of Clinical Neuroscience,2019(63):213-219. [24]Kim A,Kim M,Jeong SU,et al.Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical recurrence in men with organ confined prostate cancer[J].BMC Urology,2018,18(1):7. [25]Park JS,Koo KC,Choi IY,et al.Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy[J].Medicine,2019,98(45):e17931. [26]Park YH,Kim Y,Yu H,et al.Is lymphovascular invasion a powerful predictor for biochemical recurrence in pT3 N0 prostate cancer?Results from the K-CaP database[J].Scientific Reports,2016,6(1):25419. [27]Sargos P,Ferretti L,Gross-Goupil M,et al.Characterization of prostate neuroendocrine cancers and therapeutic management:a literature review[J].Prostate Cancer and Prostatic Diseases,2014,17(3):220-226. [28]Kardoust Parizi M,Iwata T,Kimura S,et al.Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy:A Systematic Review and Meta-Analysis[J].International Journal of Molecular Sciences,2019,20(6):1374. [29]Quek ML,Daneshmand S,Rodrigo S,et al.Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer[J].Urology,2006,67(6):1247-1252. [30]Maj-Hes AB,Mathieu R,Ozsoy M,et al.Obesity is associated with biochemical recurrence after radical prostatectomy:A multi-institutional extended validation study[J].Urologic Oncology:Seminars and Original Investigations,2017,35(7):460-461. [31]Yu YD,Byun S,Lee SE,et al.Impact of Body Mass Index on Oncological Outcomes of Prostate Cancer Patients after Radical Prostatectomy[J].Scientific Reports,2018,8(1):11962. [32]Schiffmann J,Salomon G,Tilki D,et al.Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression[J].Urologic Oncology:Seminars and Original Investigations,2017,35(5):243-249. [33]Gacci M,Russo GI,De Nunzio C,et al.Meta-analysis of metabolic syndrome and prostate cancer[J].Prostate Cancer Prostatic Dis,2017,20(2):146-155. [34]Xu X,Li Q,Chang C,et al.Metabolic Syndrome Is Not Associated With Prostate Cancer Recurrence:A Retrospective Analysis of a Chinese Cohort[J].Frontiers in Oncology,2020(10):63. [35]Morlacco A,Dal Moro F,Rangel LJ,et al.Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy[J].Urologic Oncology:Seminars and Original Investigations,2018,36(12):521-528. [36]范毛川,余沁楠,朱峰,等.腹腔镜前列腺癌根治术与开放性前列腺癌根治术治疗早期前列腺癌疗效比较[J].新乡医学院学报,2019,36(8):748-751. [37]Srougi V,Bessa J,Baghdadi M,et al.Surgical method influences specimen margins and biochemical recurrence during radical prostatectomy for high-risk prostate cancer:a systematic review and meta-analysis[J].World Journal of Urology,2017,35(10):1481-1488. [38]庞松强,罗功唐,宋瑶.3D与2D腹腔镜前列腺癌根治术治疗前列腺癌综合效果及并发症比较[J].临床外科杂志,2019,27(2):109-112. [39]袁令兴,娄庆艳,徐英民,等.新辅助内分泌治疗联合腹腔镜前列腺癌根治术治疗高危及局部晚期前列腺癌的临床研究[J].临床泌尿外科杂志,2019,34(10):801-803. [40]Hu J,Hung S,Ou Y.Assessments of Neoadjuvant Hormone Therapy Followed by Robotic-Assisted Radical Prostatectomy for Intermediate and High-Risk Prostate Cancer[J].Anticancer research,2017,37(6):3143. [41]Nunes-Silva I,Barret E,Srougi V,et al.Effect of Prior Focal Therapy on Perioperative,Oncologic and Functional Outcomes of Salvage Robotic Assisted Radical Prostatectomy[J].J Urol,2017,198(5):1069-1076.
相似文献/References:
[1]廖 祺,黄 一,徐 雪.前列腺癌骨转移的疼痛管理[J].医学信息,2018,31(06):51.[doi:10.3969/j.issn.1006-1959.2018.06.017]
LIAO Qi,HUANG Yi,XU Xue.Pain Management of Bone Metastasis in Prostate Cancer[J].Medical Information,2018,31(05):51.[doi:10.3969/j.issn.1006-1959.2018.06.017]
[2]袁长翮.超声引导下经直肠前列腺穿刺诊断前列腺癌的价值研究[J].医学信息,2018,31(04):156.[doi:10.3969/j.issn.1006-1959.2018.04.058]
YUAN Chang-he.The Value of Ultrasound Guided Transrectal Prostate Puncture in the Diagnosis of Prostate Cancer[J].Medical Information,2018,31(05):156.[doi:10.3969/j.issn.1006-1959.2018.04.058]
[3]胡春燕,吴天天,王 殊,等.前列腺癌患者自我感受负担及其影响因素研究[J].医学信息,2018,31(13):173.[doi:10.3969/j.issn.1006-1959.2018.13.054]
HU Chun-yan,WU Tian-tian,WANG Shu,et al.Study on Self-perceived Burden and its Influencing Factors in Patients with Prostate Cancer[J].Medical Information,2018,31(05):173.[doi:10.3969/j.issn.1006-1959.2018.13.054]
[4]蒋 薇.全程心理干预对前列腺癌根治术后患者焦虑抑郁情绪的影响研究[J].医学信息,2018,31(21):178.[doi:10.3969/j.issn.1006-1959.2018.21.053]
JIANG Wei.Effect of Comprehensive Psychological Intervention on Anxiety and Depression in Patients with Prostate Cancer after Radical Prostatectomy[J].Medical Information,2018,31(05):178.[doi:10.3969/j.issn.1006-1959.2018.21.053]
[5]曹志彬,王元天,杨伟忠,等.前列腺健康指数在前列腺癌早期诊断中的价值[J].医学信息,2018,31(23):29.[doi:10.3969/j.issn.1006-1959.2018.23.009]
CAO Zhi-bin,WANG Yuan-tian,YANG Wei-zhong,et al.The Value of Prostate Health Index in Early Diagnosis of Prostate Cancer[J].Medical Information,2018,31(05):29.[doi:10.3969/j.issn.1006-1959.2018.23.009]
[6]张 莹,谢 静.前列腺癌预后标志的研究[J].医学信息,2019,32(09):7.[doi:10.3969/j.issn.1006-1959.2019.09.003]
ZHANG Ying,XIE Jing.Prognostic Markers of Prostate Cancer[J].Medical Information,2019,32(05):7.[doi:10.3969/j.issn.1006-1959.2019.09.003]
[7]袁也晴,张学齐,汪青蓉,等.KIF14在前列腺癌细胞中的表达及作用[J].医学信息,2019,32(09):68.[doi:10.3969/j.issn.1006-1959.2019.09.022]
YUAN Ye-qing,ZHANG Xue-qi,WANG Qing-rong,et al.Expression and Role of KIF14 in Prostate Cancer Cells[J].Medical Information,2019,32(05):68.[doi:10.3969/j.issn.1006-1959.2019.09.022]
[8]胡嘉莉,华 琳.miRNA-mRNA双重表达谱在前列腺癌分子调控机制中的作用[J].医学信息,2022,35(16):18.[doi:10.3969/j.issn.1006-1959.2022.16.004]
HU Jia-li,HUA Lin.Role of miRNA-mRNA Dual Expression Profile in Molecular Regulation of Prostate Cancer[J].Medical Information,2022,35(05):18.[doi:10.3969/j.issn.1006-1959.2022.16.004]
[9]王 乾,孙 宾,李殷南,等.尿液中肌氨酸、PCA3mRNA在前列腺癌
早期诊断中的应用[J].医学信息,2019,32(14):175.[doi:10.3969/j.issn.1006-1959.2019.14.059]
WANG Qian,SUN Bin,LI Yin-nan,et al.Application of Urinary Sarcosine and PCA3mRNA in Early Diagnosis of Prostate Cancer[J].Medical Information,2019,32(05):175.[doi:10.3969/j.issn.1006-1959.2019.14.059]
[10]李熹阳,谷明宇,华 琳.影响前列腺癌风险的关键基因识别[J].医学信息,2020,33(02):80.[doi:10.3969/j.issn.1006-1959.2020.02.022]
LI Xi-yang,GU Ming-yu,HUA Lin.Identification of Key Genes Affecting Prostate Cancer Risk[J].Medical Information,2020,33(05):80.[doi:10.3969/j.issn.1006-1959.2020.02.022]